I'm LongbridgeAI, I can summarize articles.GRI Bio reported a Q2 2026 net loss of $1.64M and diluted EPS of $(0.91), with no operating revenue. The company secured cash through Q2 2027 via recent financing but requires additional funding for later-stage trials. Clinically, its Phase 2a trial for GRI-0621 met safety endpoints and showed supportive signals. The FDA granted Orphan Drug Designation for GRI-0621 in IPF on June 18, 2026.
GRI Bio, Inc. reported a net loss of $(1.64) M for the second quarter of 2026, with diluted loss per share of $(0.91). The company did not report operating revenue for the quarter and said recent financing activity provides cash into Q2 2027 while additional funding will be needed to advance later-stage trials.
Financial Highlights
- Net income: $(1.64) M for 2Q 2026, compared with $(2.89) M in 2Q 2025.
- Diluted earnings per share: $(0.91) for 2Q 2026, versus $(36.72) in 2Q 2025.
- Revenue: Not reported for 2Q 2026 (no operating revenues disclosed in Part 1 Item 1/Item 2).
Business Highlights
- Clinical milestone: The Phase 2a trial of GRI-0621 met its primary safety endpoint and showed supportive biomarker, RNAseq and pharmacodynamic signals consistent with activity.
- Regulatory progress: The FDA granted Orphan Drug Designation for GRI-0621 in idiopathic pulmonary fibrosis (IPF) on June 18, 2026.
- Operational focus: Management prioritized resources toward GRI-0621; development of GRI-0803 is limited pending additional funding, with IND-enabling work targeted for H1 2027.
- Clinical findings: Company reported signals of anti-fibrotic activity, trends toward improved FVC, and immune-modulation versus placebo in the Phase 2a data.
- Capital and runway: At-the-market program and recent offerings provided cash to fund operations through Q2 2027, but additional financing will be required to support further clinical trials.
Original SEC Filing: GRI Bio, Inc. [ GRI ] - 10-Q - Aug. 14, 2026